Phosphodiesterase Type 5 (PDE5) Inhibitors in Erectile Dysfunction: The Proper Drug for the Proper Patient

Journal of Sexual Medicine

Volumn 8, Issue 12, 2011, Pages 3418-3432

  Corona, Giovanni ^a,b   Mondaini, Nicola ^a   Ungar, Andrea ^a   Razzoli, Elisa ^c   Rossi, Andrea ^c   Fusco, Ferdinando ^d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c Medical Department   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Erectile dysfunction; PDE5 inhibitors; Tailored treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; INSULIN; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; LABETALOL; NEBIVOLOL; NITRATE; ORAL ANTIDIABETIC AGENT; PHOSPHODIESTERASE V INHIBITOR; PROCAINAMIDE; QUINIDINE; SILDENAFIL; SOTALOL; SPIRONOLACTONE; TADALAFIL; TESTOSTERONE; THIAZIDE DIURETIC AGENT; UDENAFIL; UNINDEXED DRUG; VARDENAFIL;

ANTICOAGULATION; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL (TOPIC); COMORBIDITY; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES MELLITUS; DISPERSIBLE TABLET; DRUG APPROVAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DYSLIPIDEMIA; EJACULATION DISORDER; ENDOCRINE DISEASE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOGONADISM; HYPOTENSION; LONG QT SYNDROME; LOWER URINARY TRACT SYMPTOM; MALE; MALE SEXUAL DYSFUNCTION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PENIS ERECTION; PREMATURE EJACULATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATECTOMY; RISK FACTOR; SEXUAL FUNCTION; SPINAL CORD INJURY; SYSTEMATIC REVIEW; TABLET FORMULATION; THROMBOSIS; TREATMENT OUTCOME;

EID: 82955203374     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02473.x     Document Type: Article

References (119)

1. Foresta C, Caretta N, Corona G, Fabbri A, Francavilla S, Jannini E, Maggi M, Bettocchi C, Lenzi A. Clinical and metabolic evaluation of subjects with erectile dysfunction: a review with a proposal flowchart. Int J Androl 2009;32:198-211.
2. Petrone L, Mannucci E, Corona G, Bartolini M, Forti G, Giommi R, Maggi M. Structured interview on erectile dysfunction (SIEDY): a new, multidimensional instrument for quantification of pathogenetic issues on erectile dysfunction. Int J Impot Res 2003;15:210-20.
3. Hatzimouratidis K. Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. Clin Interv Aging 2006;1:403-14.
4. Hatzichristou D, Rosen RC, Broderick G, Clayton A, Cuzin B, Derogatis L, Litwin M, Meuleman E, O'Leary M, Quirk F, Sadovsky R, Seftel A. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med 2004;1:49-57.
5. Wespes E, Amar E, Eardley I, Giuliano F, Hatzichristou D, Hatzimouratidis K, Montorsi F, Vardi Y. Guidelines on male sexual dysfunction: Erectile dysfunction and premature ejaculation. EAU (European Association of Urology) 2010. Available at: (accessed June 1, 2011).
6. Mirone V, Fusco F, Rossi A, Sicuteri R, Montorsi F. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies. BJU Int 2009;103:1212-7.
7. Corona G, Razzoli E, Forti G, Maggi M. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 2008;31:799-808.
8. Kouvelas D, Goulas A, Papazisis G, Sardeli C, Pourzitaki C. PDE5 inhibitors: in vitro and in vivo pharmacological profile. Curr Pharm Des 2009;15:3464-75.
9. Dorsey P, Keel C, Klavens M, Hellstrom WJ. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother 2010;11:1109-22.
10. Efficacy of Udenafil After Radical Resection for Sigmoid Colon and Rectal Cancer. Available at: (accessed February 7, 2011).
11. Sildenafil SPC. Sildenafil Summary of Product Characteristics. Available at: (accessed February 7, 2011).
12. Vardenafil SPC. Vardenafil Summary of Product Characteristics. Available at: (accessed February 7, 2011).
13. Tadalafil SPC. Tadalafil Summary of Product Characteristics. Available at: (accessed February 7, 2011).
14. Orodispersible vardenafil (Levitra) launched in UK. Available at: (accessed September 1, 2011).
15. McPartlin D, Wilson AM, Klausner AP. Update on the use of phosphodiesterase inhibitors in the treatment of erectile dysfunction. Curr Urol 2008;2:113-21.
16. Lewis RW, Fugl-Meyer KS, Corona G, Hayes RD, Laumann EO, Moreira ED Jr, Rellini AH, Segraves T. Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med 2010;7:1598-607.
17. Derogatis LR, Burnett AL. The epidemiology of sexual dysfunctions. J Sex Med 2008;5:289-300.
18. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009;94:1853-78.
19. Corona G, Mannucci E, Forti G, Maggi M, Hypogonadism ED. metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl 2009;32:587-98.
20. Sachs BD. The false organic-psychogenic distinction and related problems in the classification of erectile dysfunction. Int J Impot Res 2003;15:72-8.
21. Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev 2007;(1):CD002187.
22. Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K, Munarriz R, Lee SW. Pharmacotherapy for erectile dysfunction. J Sex Med 2010;7:524-40.
23. Gazzaruso C, Solerte SB, Pujia A, Coppola A, Vezzoli M, Salvucci F, Valenti C, Giustina A, Garzaniti A. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol 2008;51:2040-4.
24. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G, Rose L, Lording D, Liang S. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008;25:138-46.
25. Porst H, Glina S, Ralph D, Zeigler H, Wong DG, Woodward B. Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction. J Sex Med 2010;7:3487-94.
26. Corona G, Lee DM, Forti G, O'Connor DB, Maggi M, O'Neill TW, Pendleton N, Bartfai G, Boonen S, Casanueva FF, Finn JD, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Punab M, Silman AJ, Vanderschueren D, Wu FC, EMAS Study Group. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med 2010;7:1362-80.
27. Corona G, Monami M, Boddi V, Cameron-Smith M, Lotti F, de Vita G, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Male sexuality and cardiovascular risk. A cohort study in patients with erectile dysfunction. J Sex Med 2010;7:1918-27.
28. Manolis A, Doumas M. Sexual dysfunction: the "prima ballerina" of hypertension-related quality-of-life complications. J Hypertens 2008;26:2074-84.
29. Lue TF. Erectile dysfunction. N Engl J Med 2000;342:1802-13.
30. Jackson G, Rosen RC, Kloner RA, Kostis JB. The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. J Sex Med 2006;3:28-36.
31. McVary KT, Siegel RL, Carlsson M. Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of baseline body mass index or LUTS severity. Urology 2008;72:575-9.
32. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, Mitchell MI. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006;61:280-8.
33. Trocóniz IF, Tillmann C, Staab A, Rapado J, Forgue ST. Tadalafil population pharmacokinetics in patients with erectile dysfunction. Eur J Clin Pharmacol 2007;63:583-90.
34. Corona G, Mannucci E, Lotti F, Boddi V, Jannini EA, Fisher AD, Monami M, Sforza A, Forti G, Maggi M. Impairment of couple relationship in male patients with sexual dysfunction is associated with overt hypogonadism. J Sex Med 2009;6:2591-600.
35. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010;7:46-56.
36. Palumbo PJ. Metabolic risk factors, endothelial dysfunction, and erectile dysfunction in men with diabetes. Am J Med Sci 2007;334:466-80.
37. Hill KD, Eckhauser AW, Marney A, Brown NJ. Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome. Diabetes Care 2009;32:857-9.
38. Nikoobakht M, Nasseh H, Pourkasmaee M. The relationship between lipid profile and erectile dysfunction. Int J Impot Res 2005;17:523-6.
39. Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol 2004;43:1405-11.
40. Miner M, Gilderman L, Bailen J, Cook D, Dawson K, Stanislaus M, Beresford E, Barnes A. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med 2008;5:1455-67.
41. Corona G, Mannucci E, Petrone L, Ricca V, Mansani R, Cilotti A, Balercia G, Chiarini V, Giommi R, Forti G, Maggi M. Psychobiological correlates of smoking in patients with erectile dysfunction. Int J Impot Res 2005;17:527-34.
42. Chew KK, Bremner A, Stuckey B, Earle C, Jamrozik K. Is the relationship between cigarette smoking and male erectile dysfunction independent of cardiovascular disease? Findings from a population-based cross-sectional study. J Sex Med 2009;6:222-31.
43. Kupelian V, Link CL, McKinlay JB. Association between smoking, passive smoking, and erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. Eur Urol 2007;52:416-22.
44. Gades NM, Nehra A, Jacobson DJ, McGree ME, Girman CJ, Rhodes T, Roberts RO, Lieber MM, Jacobsen SJ. Association between smoking and erectile dysfunction: a population-based study. Am J Epidemiol 2005;161:346-51.
45. Pourmand G, Alidaee MR, Rasuli S, Maleki A, Mehrsai A. Do cigarette smokers with erectile dysfunction benefit from stopping?: a prospective study. BJU Int 2004;94:1310-3.
46. Imamura M, Waseda Y, Marinova GV, Ishibashi T, Obayashi S, Sasaki A, Nagai A, Azuma H. Alterations of NOS, arginase, and DDAH protein expression in rabbit cavernous tissue after administration of cigarette smoke extract. Am J Physiol Regul Integr Comp Physiol 2007;293:R2081-9.
47. Harte CB, Meston CM. Acute effects of nicotine on physiological and subjective sexual arousal in nonsmoking men: a randomized, double-blind, placebo-controlled trial. J Sex Med 2008;5:110-21.
48. Magheli A, Burnett AL. Medscape. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol 2009;6:415-27.
49. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'Dow J, Nordling J, de la Rosette JJ. Guidelines on conservative treatment of non-neurogenic male LUTS. EAU (European Association of Urology) 2010.
50. Droupy S, Giuliano F, Costa P. les membres du comité d'andrologie de l'AFU. Erectile rehabilitation after radical prostatectomy. Prog Urol 2009;19(suppl 4):S193-97.
51. Shindel AW. 2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). J Sex Med 2009;6:1794-808.
52. Soler JM, Previnaire JG, Denys P, Chartier-Kastler E. Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men. Spinal Cord 2007;45:169-73.
53. Lombardi G, Macchiarella A, Cecconi F, Del Popolo G. Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients. J Sex Med 2009;6:1248-58.
54. Corona G, Petrone L, Mannucci E, Magini A, Lotti F, Ricca V, Chiarini V, Forti G, Maggi M. Assessment of the relational factor in male patients consulting for sexual dysfunction: the concept of couple sexual dysfunction. J Androl 2006;27:795-801.
55. Conaglen HM, Conaglen JV. Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study. J Sex Med 2008;5:1198-207.
56. Jannini EA, McCabe MP, Salonia A, Montorsi F, Sachs BD. Organic vs. psychogenic? The Manichean diagnosis in sexual medicine. J Sex Med 2010;7:1726-33.
57. Corona G, Ricca V, Bandini E, Mannucci E, Petrone L, Fisher AD, Lotti F, Balercia G, Faravelli C, Forti G, Maggi M. Association between psychiatric symptoms and erectile dysfunction. J Sex Med 2008;5:458-68.
58. Corona G, Ricca V, Bandini E, Mannucci E, Lotti F, Boddi V, Rastrelli G, Sforza A, Faravelli C, Forti G, Maggi M. Selective serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Med 2009;6:1259-69.
59. Shiri R, Koskimäki J, Tammela TL, Häkkinen J, Auvinen A, Hakama M. Bidirectional relationship between depression and erectile dysfunction. J Urol 2007;177:669-73.
60. Bandini E, Fisher AD, Corona G, Ricca V, Monami M, Boddi V, Balzi D, Melani C, Forti G, Mannucci E, Maggi M. Severe depressive symptoms and cardiovascular risk in subjects with erectile dysfunction. J Sex Med 2010;7:3477-86.
61. Seidman SN, Roose SP, Menza MA, Shabsigh R, Rosen RC. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001;158:1623-30.
62. Rosen R, Shabsigh R, Berber M, Assalian P, Menza M, Rodriguez-Vela L, Porto R, Bangerter K, Seger M, Montorsi F, Vardenafil Study Site Investigators. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Am J Psychiatry 2006;163:79-87.
63. Bocchio M, Pelliccione F, Mihalca R, Ciociola F, Necozione S, Rossi A, Francavilla F, Francavilla S. Treatment of erectile dysfunction reduces psychological distress. Int J Androl 2009;32:74-80.
64. Corona G, Jannini EA, Lotti F, Boddi V, De Vita G, Forti G, Lenzi A, Mannucci E, Maggi M. Premature and delayed ejaculation: two ends of a single continuum influenced by hormonal milieu. Int J Androl 2011;34:41-8.
65. Jannini EA, Lenzi A. Ejaculatory disorders: epidemiology and current approaches to definition, classification and subtyping. World J Urol 2005;23:68-75.
66. Colpi G, Weidner W, Jungwirth A, Pomerol J, Papp G, Hargreave T, Dohle G, EAU Working Party on Male Infertility. EAU guidelines on ejaculatory dysfunction. Eur Urol 2004;46:555-8.
67. Rowland D, McMahon CG, Abdo C, Chen J, Jannini E, Waldinger MD, Ahn TY. Disorders of orgasm and ejaculation in men. J Sex Med 2010;7:1668-86.
68. Corona G, Boddi V, Gacci M, Sforza A, Forti G, Mannucci E, Maggi M. Perceived Ejaculate Volume Reduction in Subjects with Erectile Dysfunction: Psycho-Biological Correlates. J Androl 2011;32:333-9.
69. Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin A, Meuleman E, Eardley I, Dean JD, Shabsigh R. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011;8:284-93.
70. Corona G, Petrone L, Mannucci E, Ricca V, Balercia G, Giommi R, Forti G, Maggi M. The impotent couple: low desire. Int J Androl 2005;28(suppl 2):46-52.
71. Wu FC, Tajar A, Beynon JM, Pye SR. Silman AJ, Finn JD, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Boonen S, Vanderschueren D, Labrie F, Huhtaniemi IT, EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123-35.
72. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol 2005;63:381-94.
73. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol 2003;58:632-8.
74. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94-9.
75. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:658-63.
76. Chatterjee R, Wood S, McGarrigle HH, Lees WR, Ralph DJ, Neild GH. A novel therapy with testosterone and sildenafil for erectile dysfunction in patients on renal dialysis or after renal transplantation. J Fam Plann Reprod Health Care 2004;30:88-90.
77. Foresta C, Caretta N, Rossato M, Garolla A, Ferlin A. Role of androgens in erectile function. J Urol 2004;171:2358-62.
78. Shamloul R, Ghanem H, Fahmy I, El-Meleigy A, Ashoor S, Elnashaar A, Kamel I. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med 2005;2:559-64.
79. Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? J Urol 2005;173:530-2.
80. Tas A, Ersoy A, Ersoy C, Gullulu M, Yurtkuran M. Efficacy of sildenafil in male dialysis patients with erectile dysfunction unresponsive to erythropoietin and/or testosterone treatments. Int J Impot Res 2006;18:61-8.
81. Rochira V, Balestrieri A, Madeo B, Granata AR, Carani C. Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. J Androl 2006;27:165-75.
82. Hwang TI, Chen HE, Tsai TF, Lin YC. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res 2006;18:400-4.
83. Rosenthal BD, May NR, Metro MJ, Harkaway RC, Ginsberg PC. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006;67:571-4.
84. Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia 2006;38:61-8.
85. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
86. Wespes E, Moncada I, Schmitt H, Jungwirth A, Chan M, Varanese L. The influence of age on treatment outcomes in men with erectile dysfunction treated with two regimens of tadalafil: results of the SURE study. BJU Int 2007;99:121-6.
87. Seftel AD. Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. J Urol 2003;169:1999-2007.
88. Forgue ST, Phillips DL, Bedding AW, Payne CD, Jewell H, Patterson BE, Wrishko RE, Mitchell MI. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics. Br J Clin Pharmacol 2007;63:24-35.
89. Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol 2002;53(suppl 1):21S-30S.
90. Porst H, Young JM, Schmidt AC, Buvat J, International Vardenafil Study Group. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology 2003;62:519-24.
91. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, Walker DJ, Shen W, Cordell WH. The efficacy and safety of tadalafil: an update. BJU Int 2004;93:1276-81.
92. Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002;60(2 suppl 2):12-27.
93. Dimitriadis F, Tsounapi P, Saito M, Watanabe T, Sylakos A, Tsabalas S, Miyagawa I, Sofikitis N. Is there a role for PDE5 inhibitors in the management of male infertility due to defects in testicular or epididymal function? Curr Pharm Des 2009;15:3506-20.
94. Foresta C, De Toni L, Selice R, Garolla A, Di Mambro A. Increased osteocalcin-positive endothelial progenitor cells in hypogonadal male patients. J Endocrinol Invest 2010;33:439-42.
95. Aversa A, Mazzilli F, Rossi T, Delfino M, Isidori AM, Fabbri A. Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males. Hum Reprod 2000;15:131-4.
96. Pomara G, Morelli G, Canale D, Turchi P, Caglieresi C, Moschini C, Liguori G, Selli C, Macchia E, Martino E, Francesca F. Alterations in sperm motility after acute oral administration of sildenafil or tadalafil in young, infertile men. Fertil Steril 2007;88:860-5.
97. Hellstrom WJ, Gittelman M, Jarow J, Steidle C, McMurray J, Talley D, Watts S, Mitchell CL, McGill JM. An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20 mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. Eur Urol 2008;53:1058-65.
98. Jarvi K, Dula E, Drehobl M, Pryor J, Shapiro J, Seger M. Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with normal baseline levels. J Urol 2008;179:1060-5.
99. Matic H, McCabe MP. Duration of erectile dysfunction and its relationship to treatment seeking and satisfaction with treatment using PDE5 inhibitors. Int J Urol 2008;15:346-9.
100. McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ 2006;332:589-92.
101. Bella AJ, Brock GB. Strategies for PDE-5 Failures. Geriatr Aging 2006;9(suppl 9):9-15.
102. Hackett GI. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. Clin Cornerstone 2005;7:57-65.
103. Martin-Morales A, Haro JM, Beardsworth A, Bertsch J, Kontodimas S, EDOS Group. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: Results from the erectile dysfunction observational study (EDOS). Eur Urol 2007;51:541-50.
104. Conaglen HM, Conaglen JV. The impact of erectile dysfunction on female partners: A qualitative investigation. Sex Relat Ther 2008;23:147-56.
105. Fisher WA, Rosen RC, Eardley I, Sand M, Goldstein I. Sexual experience of female partners of men with erectile dysfunction: The female experience of men's attitudes to life events and sexuality (FEMALES) study. J Sex Med 2005;2:675-84.
106. Klotz T, Mathers M, Klotz R, Sommer F. Patients responding to phosphodiesterase type 5 inhibitor therapy: What do their sexual partners know? J Sex Med 2007;4:162-5.
107. Hatzichristou D, Vardi Y, Papp G, Pushkar D, Basson BR, Kopernicky V. Effect of tadalafil on sexual timing behavior patterns in men with erectile dysfunction: Integrated analysis of randomized, placebo controlled trials. J Urol 2005;174:1356-9.
108. Paul JP, Pollack L, Osmond D, Catania JA. Viagra (sildenafil) use in a population-based sample of U.S. men who have sex with men. Sex Transm Dis 2005;32:531-3.
109. Sanchez TH, Gallagher KM. Factors associated with recent sildenafil (viagra) use among men who have sex with men in the United States. J Acquir Immune Defic Syndr 2006;42:95-100.
110. Chu PL, McFarland W, Gibson S, Weide D, Henne J, Miller P, Partridge T, Schwarcz S. Viagra use in a community-recruited sample of men who have sex with men, San Francisco. J Acquir Immune Defic Syndr 2003;33:191-3.
111. Nettles CD, Benotsch EG, Uban KA. Sexual risk behaviors among men who have sex with men using erectile dysfunction medications. AIDS Patient Care STDS 2009;23:1017-23.
112. Patterson B, Bedding A, Forgue ST, Jewell H, Payne C, Mitchell M. Dose-normalized pharmacokinetics of single-dose tadalafil (IC351) in healthy volunteers. Int J Impot Res 2001;13(suppl 5):S62.
113. Mehrotra N, Gupta M, Kovar A, Meibohm B. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 2007;19:253-64.
114. Horvath KJ, Calsyn DA, Terry C, Cotton A. Erectile dysfunction medication use among men seeking substance abuse treatment. J Addict Dis 2007;26:7-13.
115. Halkitis PN, Green KA. Sildenafil (Viagra) and club drug use in gay and bisexual men: The role of drug combinations and context. Am J Men's Health 2007;1:139-47.
116. Smith KM, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J Am Pharm Assoc 2005;45:63-72.
117. Ljunggren C, Hedelin H, Salomonsson K, Ströberg P. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. J Sex Med 2008;5:469-75.
118. Ströberg P, Hedelin H, Bergström A. Is sex only for the healthy and wealthy? J Sex Med 2007;4:176-82.
119. Teloken P, Mesquita G, Montorsi F, Mulhall J. Post-radical prostatectomy pharmacological penile rehabilitation: Practice patterns among the international society for sexual medicine practitioners. J Sex Med 2009;6:2032-8.